The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ASH 2018 | Practice changing abstracts in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Stefano Luminari
Gilles Salles
Francesc Bosch
Anton HagenbeekDid you miss ASH 2018? The Lymphoma Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA and has developed a downloadable resource, which provides information on the practice changing abstracts across lymphoma and CLL.
Our selection of ASH 2018 abstracts include comments from The Lymphoma Hub Steering Committee members Stefano Luminari and Gilles Salles on ibrutinib combination therapies for the front-line treatment of CLL, and the role of the lenalidomide and rituximab combination in relapsed follicular lymphoma. Hear from the experts on the role of mutations that confer resistance to venetoclax and whether less is more when it comes to front line treatment in patients with DLBCL.
References